Linzolid 400 Tablet 1 Strip

✔️ Dosage & Administration

Linzolid is available as oral tablets and intravenous infusion. It can be taken with or without food. IV infusion must be administered over 30–120 minutes.

Neonates (<7 days, <34 weeks GA): Begin with 10 mg/kg every 12 hours. If clinical response is inadequate, 10 mg/kg every 8 hours may be considered. By day 7, switch to 10 mg/kg every 8 hours.

No dose adjustment is needed when switching between IV and oral forms.

IV Administration: Inspect the infusion visually for particulates. A yellow tint may develop without affecting potency. Avoid series connections or adding substances to the solution. Discard any unused solution after a single use.

Hepatic impairment: No adjustment needed in mild-to-moderate cases. Not studied in severe hepatic dysfunction.

Pediatric CNS infections: Not recommended for empirical treatment.

✔️ Adverse Effects

• Diarrhea
• Nausea
• Headache

✔️ Drug Interactions

With medications: Linezolid is a reversible non-selective MAO inhibitor. It may enhance the pressor response to sympathomimetics and pose a risk of serotonin syndrome when co-administered with SSRIs, TCAs, triptans, buspirone, or meperidine.

With food: Patients should avoid tyramine-rich foods (e.g., aged cheese, fermented meats).

✔️ Contraindications

• Known hypersensitivity to Linezolid or its components.
• Concomitant use with MAO inhibitors (e.g., phenelzine, isocarboxazid) or within 2 weeks of their use.
• Conditions such as uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome, or concurrent use of certain serotonergic or adrenergic agents.
• Others: Oral/vaginal candidiasis, hypertension, indigestion, abdominal discomfort, itching, and tongue discoloration.

✔️ Use in Pregnancy and Lactation

Pregnancy: Limited data suggest no major fetal risks. Use only if needed.

Breastfeeding: Linezolid is present in breast milk. Monitor infants for gastrointestinal symptoms.

✔️ Precautions & Warnings

• Monitor CBC weekly, especially with prolonged use (>2 weeks), in patients with prior myelosuppression or receiving other marrow-suppressing drugs.
• If visual disturbances occur, prompt ophthalmic evaluation is necessary.
• Not recommended for catheter-related bloodstream or catheter-site infections.
• Be alert for Clostridium difficile-associated diarrhea (CDAD), which may occur up to 2 months post-treatment.
• Monitor blood pressure in susceptible individuals.
• Patients with unexplained acidosis or hypoglycemia should receive immediate medical attention and potential treatment adjustments.